Passionate about improving lives through the development of Link_TSG6

Reuben Dawkins - Chief Executive Officer

Reuben Dawkins is a strategic and entrepreneurial leader with fifteen years hands-on experience within the biopharmaceutical industry.  Reuben has held several commercial roles of increasing responsibility across therapy areas for multinational companies including Glaxosmithkline, Bayer and Novo Nordisk. His most recent roles for Novo Nordisk have included Business Unit Head, Global Life Cycle Management Lead for a $1bn+ product portfolio, and Global Product Director for multiple early-stage assets targeting billion-dollar markets. Reuben holds a BSc (Hons) in Chemistry with Business Management from the University of Leicester and an MSc with distinction in Drug Design from University College London (UCL).

Tony Day - Chief Scientific Officer

Tony Day is a Professor of Biochemistry within the Faculty of Biology, Medicine and Health (FBMH), University of Manchester, UK. He is Lead for Translation at the Wellcome Centre for Cell-Matrix Research and a member of the Lydia Becker Institute of Immunology and Inflammation. Tony is a matrix biologist with a major interest in the role of glycosaminoglycan-protein interactions during inflammation. For example, along with Caroline Milner he has published seminal papers on TSG-6, underpinning the development of Link_TSG6 as a biological drug. Tony (who has an H-index of >80) was elected to the Academy of Europe in 2012, is a former member of the Council of the International Society for Matrix Biology, was Chair of the Gordon Research Conference on Proteoglycans in 2018 and President of the International Society for Hyaluronan Sciences (2020-2023). Tony holds a BA (Hons) in Chemistry and a DPhil in Biochemistry from the University of Oxford.

Caroline Milner - Scientific Director

Caroline Milner is a Senior Lecturer in Immune Response and Disease within FBMH, University of Manchester, UK. Caroline is a member of the leadership team for the Division of Cell Matrix Biology and Regenerative Medicine and is affiliated to the Manchester Regenerative Medicine Network and the Lydia Becker Institute of Immunology and Inflammation. Caroline’s major interests are in the regulation of inflammatory and immune processes as potential therapeutic targets. With Tony Day, she has co-led work on TSG-6 for ~20 years, having raised significant funding for basic and translational research and published key papers. Caroline holds a BA in Chemistry and a DPhil in Biochemistry from the University of Oxford.